Bethiolum rectal suppositories (candles) 10 pcs.

• active ingredient: belladonnae extract dense, ichthammol;
• 1 suppository contains: belladonna extract thick ((4.8-5.2) : 1) (Belladonnae extractum spissum) extractant 20% (v/v) ethanol)) (calculated as the sum of alkaloids 0.00023 g) – 0.015 g (15 mg), ichthammol – 0.2 g (200 mg);
• excipient: solid fat.

Hypersensitivity to belladonna or to other components of the drug. Cardiovascular diseases in which an increase in heart rate may be undesirable: atrial fibrillation, tachycardia, chronic heart failure, ischemic heart disease, mitral stenosis, severe arterial hypertension. Glaucoma. Urinary retention or tendency to it, prostate adenoma. Myasthenia gravis. Gastrointestinal diseases accompanied by obstruction. Hyperthermic syndrome. Thyrotoxicosis. Acute bleeding.

Gastrointestinal disorders: dry mouth, thirst, taste disturbances, dysphagia, decreased intestinal motility up to atony, decreased tone of the biliary tract and gallbladder.

Renal and urinary disorders: difficulty and retention of urination.

Cardiac disorders: palpitations; arrhythmia, including extrasystole; myocardial ischemia.

Vascular disorders: facial flushing, hot flashes.

Neurological disorders: headache, dizziness.

On the part of the organs of vision: dilated pupils, photophobia, accommodation paralysis, increased intraocular pressure.

On the part of the respiratory system and mediastinal organs: a decrease in secretory activity and bronchial tone, which leads to the formation of viscous sputum that is difficult to cough up.

Skin and subcutaneous tissue disorders: skin rash, urticaria, exfoliative dermatitis, hyperemia.

Immune system disorders: anaphylactic reactions, anaphylactic shock.

Adults should use 1 suppository rectally 1–3 times a day. The duration of treatment is determined by the doctor individually, taking into account the nature and severity of the disease and the achieved therapeutic effect. More frequent use is allowed if prescribed by a doctor.

Use during pregnancy or breastfeeding

During pregnancy or breastfeeding, the drug can be used only as prescribed by a doctor if the expected benefit to the woman outweighs the potential risk to the fetus/child.

Children

There is no data on the use of the drug in children.

Ability to influence reaction speed when driving vehicles or other mechanisms

When treating with the drug, it is recommended to refrain from driving vehicles or performing work that requires increased attention and precise coordination.

Symptoms: increased manifestations of adverse reactions, nausea, vomiting, tachycardia, decreased blood pressure, agitation, irritability, tremor, convulsions, insomnia, drowsiness, hallucinations, hyperthermia, depression of the central nervous system, depression of the activity of the respiratory and vasomotor centers, dry mouth, thirst, constipation, dilated pupils.

Poisoning causes delirium with psychomotor agitation, which requires special therapy.

Treatment: Parenteral administration of cholinomimetics and anticholinesterase agents. Treatment is symptomatic.

When used with monoamine oxidase inhibitors, cardiac arrhythmias occur, with quinidine, novocainamide – an additive anticholinergic effect is observed. May reduce the duration and depth of action of narcotic drugs, weakens the analgesic effect of opiates.

When used simultaneously with diphenhydramine or diprazine, the effect of the drug is enhanced, with nitrates, haloperidol, corticosteroids for systemic use – the likelihood of increasing intraocular pressure increases, with sertraline – the depressive effect of both drugs is enhanced, with spironolactone, minoxidil – the effect of spironolactone and minoxidil is reduced, with penicillins – the effect of both drugs is enhanced, with nizatidine – the effect of nizatidine is enhanced, with ketoconazole – the absorption of ketoconazole is reduced, with ascorbic acid and attapulgite – the effect of atropine is reduced, with pilocarpine – the effect of pilocarpine in the treatment of glaucoma is reduced, with oxprenolone – the antihypertensive effect of the drug is reduced. Under the action of Octadine, a decrease in the hyposecretory effect of atropine is possible, which weakens the effect of M-cholinomimetics and anticholinesterase agents. When used simultaneously with sulfonamide drugs, the risk of kidney damage increases, with drugs containing potassium, the formation of intestinal ulcers is possible, with nonsteroidal anti-inflammatory drugs the risk of stomach ulcers and bleeding increases.

The effect of the drug may be enhanced by the simultaneous use of other drugs with antimuscarinic effect: M-cholinoblockers, antiparkinsonian drugs (amantadine), antispasmodics, some antihistamines, butyrophenone drugs, phenothiazines, dispyramides, quinidine and tricyclic antidepressants, non-selective inhibitors of neuronal monoamine reuptake.

Inhibition of peristalsis by atropine may alter the absorption of other drugs.

Store at a temperature not exceeding 25C.

Keep out of reach of children.